Assessing Immune Dysfunction in Sepsis

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
University of Minnesota
Study ID
NCT07154615
Status
Recruiting
Apply to this trial

Conditions

  • Sepsis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Observational Only — OTHER
    No intervention is included in this study

Study Details

Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.

Key Dates

Start date
Mar 1, 2026
Status verified
Mar 2026
Primary completion
Nov 1, 2028
Completion
Nov 1, 2028

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: ICU Patients with Sepsis
  • Arm: ICU Patients without Sepsis
  • Arm: Healthy Volunteers

Primary Outcome Measure

EliSpot - Day 1 [ Time Frame: Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MinnesotaMinneapolisMinnesota55455
Kristine Kancans
[email protected]

Find similar trials in Minneapolis, MN

By research site
University of Minnesota· Minneapolis, MN

Related Studies